Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.37 |
| ▸ | HTR3B | O95264 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22617776 | 0.82 | TSHR (0.39) | CYP3A4TSHRMEN1KMT2AHTR3E | |
| SCHEMBL4271497 | 0.82 | NCF1 (0.52) | NCF1CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL16114069 | 0.79 | CNR1 (0.44) | CYP3A4TSHRKMT2ACNR1HTR3E | |
| SCHEMBL20758812 | 0.76 | PDE10A (0.39) | NCF1PDE10A | |
| SCHEMBL14627577 | 0.76 | CYP3A4 (0.42) | CYP3A4TSHRMEN1KMT2AHTR3E | |
| SCHEMBL2308330 | 0.73 | CCR1 (0.50) | NCF1CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL31415250 | 0.73 | CCR1 (0.50) | NCF1CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL3924623 | 0.73 | CYP3A4 (0.32) | CYP3A4TSHRMEN1KMT2AHTR3E | |
| SCHEMBL58195 | 0.73 | — | — | |
| SCHEMBL11621298 | 0.71 | NCF1 (0.43) | NCF1CYP3A4TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2022-04-21 | — | — | US | disclosed |
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2022-04-21 | — | — | US | disclosed |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-11-02 | — | — | US | disclosed |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-11-02 | — | — | US | disclosed |
| US-11028067-B2 | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-06-08 | — | — | US | disclosed |
| US-11028067-B2 | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-06-08 | — | — | US | disclosed |
| US-10899710-B2 | Pyridines and their use in the treatment of cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-20200223819-A1 | HETEROARYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2020-07-16 | — | — | US | disclosed |
| US-20200223819-A1 | HETEROARYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2020-07-16 | — | — | US | disclosed |
| US-20200087260-A1 | PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | The USA, as Represented by the Secretary, Department pf Health and Human Services (US) | 2020-03-19 | — | — | US | disclosed |
| CN-105745214-B | Tricyclic piperidine compounds | 埃科特莱茵药品有限公司 | 2019-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | NCF1 2517/4885CYP3A4 101/4885TSHR 1159/4885 |
| US-20200223819-A1 | HETEROARYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | TP53, GLS2, KRAS | NCF1 2593/4885CYP3A4 238/4885TSHR 898/4885 |
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | NCF1 2517/4885CYP3A4 101/4885TSHR 1159/4885 |
| US-10899710-B2 | Pyridines and their use in the treatment of cancer | TP53, NDUFS3, NDUFS2 | NCF1 1499/4885CYP3A4 249/4885TSHR 538/4885 |
| US-20200087260-A1 | PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | TP53, NDUFS3, NDUFS2 | NCF1 1499/4885CYP3A4 249/4885TSHR 538/4885 |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | HCCS, ABL1, IDH1 | NCF1 2517/4885CYP3A4 101/4885TSHR 1159/4885 |
| US-11028067-B2 | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | TP53, GLS2, KRAS | NCF1 2593/4885CYP3A4 238/4885TSHR 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.